课题基金 / 基金详情

Role of S6 Kinase 2 in Aging

Role of S6 Kinase 2 in Aging
S6 激酶 2 在衰老中的作用
批准号:
8843321
负责人:
Remi-Martin Laberge
金额:
$9.71万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2016-04-30

项目摘要

项目成果

Remi-Martin Laberge的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):由蛋白质TOR(雷帕霉素的靶标)控制的营养感知途径的调节导致各种生物体的寿命延长。这一发现对人类的健康具有突出的潜在好处。然而,未能了解其作用机制已经减缓了其临床健康益处的应用。化合物雷帕霉素可从药理上抑制哺乳动物的TOR复合体1(MTORC1)。雷帕霉素主要通过S6Kinase1和S6K2(S6K1和S6K2)抑制特定的TOR活性。雷帕霉素延长雄性和雌性小鼠的寿命,但也通过未知的机制对健康产生负面影响。S6K1基因缺陷的雌性小鼠寿命延长,但雄性小鼠寿命延长,这表明另一种激酶S6K2在雷帕霉素延长寿命的过程中发挥了作用。此外,还没有关于S6K2缺陷小鼠寿命的数据。有趣的是,S6K2被认为与保护细胞免受凋亡有关。另一种肿瘤抑制机制是细胞衰老(一种永久性的细胞生长停止程序)。可能表达S6K2的细胞更倾向于衰老而不是凋亡,这可能是一种保护肿瘤消失的机制。随着年龄的增长,细胞衰老积累被广泛认为是衰老表型的一个贡献因素。这些细胞分泌促炎细胞因子,这种表型被称为SASP,即衰老相关的分泌表型,因此,它们在衰老生物体中的积累可能导致慢性炎症,从而刺激与年龄相关的病理现象的出现。最近,有研究表明,在孕激素小鼠模型中,衰老细胞的清除可以减轻与年龄相关的表型。我的初步数据显示,在培养的衰老细胞中,雷帕霉素减少了这些促炎细胞因子的产生,并且通过下调S6K2而不是S6K1获得了类似的结果。我的假设是,S6K2活性的降低通过缓解衰老小鼠的衰老表型来延长健康和寿命。我的研究建议将检验这样一个假设,即用雷帕霉素或其他方法抑制复杂活性会通过抑制S6K2活性来降低SASP,特别是其促炎臂。我将进一步测试抑制S6K2活性会延长小鼠寿命和健康寿命的假设。此外,我将探索S6K2的作用机制,并确定其主要底物。我将通过评估S6K2缺陷细胞和小鼠以及表达或缺失S6K2的人成纤维细胞的细胞、组织表型和生理学来实现这些目标。我将使用先进的生化和细胞生物学技术检查细胞、组织和动物的相关表型。这一奖项将成为我实现作为教授的职业目标和制定改善人类健康战略的科学目标的跳板。该奖项的指导部分将为我提供必要的技能,以实现科学独立和实现我的短期科学目标。为了实现这一目标,我将得到众多合作者的帮助,但也会得到两个领域的导师和专家的帮助(朱迪思·坎皮西博士的衰老和理查德·米勒博士的老鼠健康)。我的两位导师也将帮助我准备成为一名科学和个人层面的老龄化领域的助理教授。此外,在指导阶段,我将参加加州大学戴维斯分校的组织学强化课程。然后,我将全副武装地接受该奖项的独立部分,在那里我将继续研究S6K2耗尽对体内细胞衰老的影响及其对小鼠健康寿命的作用。
英文摘要
DESCRIPTION (provided by applicant): Modulation of the nutrient sensing pathway governed by the protein TOR (target of rapamycin) leads to lifespan extension in various organisms. This discovery has outstanding potential health benefits for humans. However, failure to understand its mechanisms of action has slowed down its application for clinical healthspan benefits. The mammalian TOR complex 1 (mTORC1) can be pharmacologically inhibited with the compound rapamycin. Rapamycin inhibits a particular subset of TOR activity, mainly through S6 Kinase 1 and 2 (S6K1 and S6K2). Rapamycin extends lifespan of male and female mice, but also has negative effect on health via unknown mechanisms. S6K1-deficient female mice, but not male mice, have an extended lifespan suggesting a role for the other kinase, S6K2, in the lifespan extension by rapamycin. Also, no data is available regarding the lifespan of S6K2-deficient mice. Interestingly, S6K2 has been link to protect cells against apoptosis. Another, tumor suppressor mechanism is cellular senescence (a permanent cell growth arrest program). It is possible that cells expressing S6K2 favor senescence rather than apoptosis as a mechanism to protect against tumor apparition. Cellular senescence accumulation with age is widely seen as a contributor of aging phenotypes. These cells secrete proinflammatory cytokines a phenotype termed SASP for senescence- associated secretory phenotype and, therefore, their accumulation in an aging organism could contribute to chronic inflammation known to stimulate the apparition of age-related pathologies. Recently, it was shown that clearance of senescent cells alleviates age-related phenotypes in the progeroid mouse model. My preliminary data show that, in senescent cells in culture, rapamycin decreases the production of these proinflammatory cytokines and that similar results are obtained by downregulating S6K2, but not S6K1. My hypothesis is that reduction of S6K2 activity extends health- and lifespan by alleviating the senescent phenotype in aging mice. My research proposal will test the hypothesis that dampening complex activity by rapamycin or other means decreases the SASP, particularly its pro-inflammatory arm, by suppressing S6K2 activity. I will further test the hypothesis that suppression of S6K2 activity results in extension of both lifespan and healthspan in mice. Further, I will explore the mechanisms by which S6K2 acts and identify its major substrates. I will accomplish these aims by evaluating cells, tissues phenotypes and the physiology of S6K2 deficient cells and mice, as well as S6K2-expressing or -depleted human fibroblasts. I will examine the cells, tissues and animals for the relevant phenotypes using advanced biochemical and cell biological techniques. This award will serve me as a springboard to achieve my career goal for being professor and my scientific goals of developing strategies to ameliorate human healthspan. The mentored portion of the award will provide me with the necessary skills to achieve scientific independence and accomplish my short-term scientific goal. To achieve that I will received the help of numerous collaborators but also from two mentors experts in the two respective fields (senescence with Dr. Judith Campisi and mice healthspan with Dr. Richard Miller). My two mentors will also help for my preparation to become an assistant professor in the field of aging both at the scientific and personal level. In addition during the mentored phase I will take an intensive histology class from UC Davis. I will then be fully armed to embrace the independent portion of the award where I will continue studying the effects that S6K2 depletion on cellular senescence in vivo and its role on mice healthspan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of S6 Kinase 2 in Aging
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: